Holds 2 active US DMFs and one valid CEP for rivaroxaban, filing since 2014. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2020. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds one active US DMF and 4 valid CEPs for rivaroxaban, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2022. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Holds one active US DMF and 4 valid CEPs for rivaroxaban, filing since 2014. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2024. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2013. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 9 markets.
Holds 2 active US DMFs and 2 valid CEPs for rivaroxaban, filing since 2014. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds 2 active US DMFs and one valid CEP for rivaroxaban, filing since 2017. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF and 4 valid CEPs for rivaroxaban, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 2 active US DMFs and one valid CEP for rivaroxaban, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs and one valid CEP for rivaroxaban, filing since 2016. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2023. Its 2024 FDA inspection closed as NAI.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2022. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2021. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2019. Its 2019 FDA inspection closed as NAI.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2021. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one valid CEP for rivaroxaban, filing since 2026. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.
Holds one active US DMF and one valid CEP for rivaroxaban, filing since 2023. Its 2025 FDA inspection closed as VAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free| Year | Median | Exporters |
|---|---|---|
| 2026 YTD | $489.38 | 15 |
| 2025 | $597.43 | 56 |
| 2024 | $692.46 | 39 |
| 2023 | $915.71 | 42 |
US dollars per kilogram, customs export unit values.